AMENDMENTS TO THE SPECIFICATION

Page 9, amend Example 1 to read as follows:

Example 1: 1-[4-[((2S)-2-amino-2-methylethyl)-amino]N2-[[4'-(octyloxy) [1,1'-biphenyl]-4-yl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]5-L-serine ~~echinocandine~~ echinocandin B trifluoroacetate (isomer A and isomer B).

Page 9, amend Stage A to read as follows:

Stage A: 1-[(4R,5R)-4,5-dihydroxy-N2-[[4'-(octyloxy) [1,1'-biphenyl]-4-yl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxy-phenyl)-L-threonine]-5-L-serine ~~echinocandine~~ echinocandin B.

Page 11, amend the first paragraph to read as follows:

few minutes at 20°C. 6 mg of $NaBH_3CN$ is introduced. Agitation is carried out for 15 hours at 20°C and after semi-preparative HPLC purification (eluent: CH_3CN, H_2OTFA (50-50-0.02) , 11.5 mg of isomer A, 13 mg of isomer B are obtained.

Example 2: 1-[4-[[(1H-benzimidazol-2-yl)-methyl~~)~~]-amino]-N2-[[4''-(pentyloxy) [1,1' : 4', 1''-terphenyl]-4-yl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine ~~echinocandine~~ echinocandin B trifluoroacetate (isomer B).

Page 11, amend the second full paragraph to read as follows:

By operating as previously starting from the nucleus of deoxymulundocandine prepared

in Preparation 1 and obtaining 1-[(4R,5R)-4,5-dihydroxy-N2-[[4"-(pentyloxy) [1,1': 4', 1"-terphenyl]-4-yl]carbonyl]-L-threonine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-~~echinocandine~~ echinocandin B as int ermediate product and the corresponding 4-oxo derivative, the sought product was obtained. Isomer A = 7.4 mg, isomer B = 1.2 mg.

Page 11, amend Example 4 to read as follows:

Example 4: 1-[4-[(2(S)-aminopropyl)-amino]-N2-[[4"-(pentyloxy) [1,1' : 4', 1"-terphenyl]-4-yl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-~~echinocandine~~ echinocandin B trifluoracetate (isomer A).